Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Technology cost versus benefits

This article was originally published in The Gray Sheet

Executive Summary

HHS task force charged with encouraging medical innovation should consider ways HHS "can document and measure the collective value to society of advances in healthcare, to ensure that the benefits of innovation are fully recognized and accounted for," The Value Group maintains in an 1Aug. 23 letter. Comprised of healthcare industry leaders, including AdvaMed, The Value Group released a report touting the benefits of new technology earlier this year (2"The Gray Sheet" Feb. 2, 2004, p. 3)...

You may also be interested in...

New Technology Benefits Quantified In Report Funded By Health Coalition

Medical technology advances from 1980-2000 helped prevent 470,000 deaths, 2.3 mil. disabilities and 206 mil. days spent in the hospital, according to a study released Jan. 28

Manufacturers Want Delay In Conducting US Nitrosamine Risk Assessments

Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.

Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy

Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts